Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Eribulin mesylate is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic breast cancer patients who progressed after at least one chemotherapy for advanced disease

Qi Zhao; Rachel Hughes; Binod Neupane; Kristin Mickle; Yun Su; Isabelle Chabot; Marissa Betts; Ananth Kadambi


Scholarcy highlights

Need more features? Save interactive summary cards to your Scholarcy Library.